Journal of Bacteriology & Parasitology

Biochemical characterization of CTX-M-15 from Enterobacter cloacae and designing a novel non- β-lactam-β-lactamase inhibitor

2^nd International Congress on Bacteriology & Infectious Diseases

November 17-19, 2014 DoubleTree by Hilton Hotel Chicago-North Shore, USA

Mohammad Faheem, Md. Tabish Rehman, Md. Danishuddin and Asad U Khan

Accepted Abstracts: J Bacteriol Parasitol

Abstract:

The worldwide dissemination of CTX-M type β-lactamases is a threat to human health. Previously, we have reported the spread of blaCTX-M-15 gene in different clinical strains of Enterobacteriaceae from the hospital settings of Aligarh in north India. In view of the varying resistance pattern against cephalosporins and other β-lactam antibiotics, we intended to understand the correlation between MICs and catalytic activity of CTX-M-15. In this study, steady-state kinetic parameters and MICs were determined on E. coli DH5α transformed with blaCTX-M-15 gene that was cloned from Enterobacter cloacae (EC-15) strain of clinical background. The effect of conventional β-lactamase inhibitors (clavulanic acid, sulbactam and tazobactam) on CTX-M-15 was also studied. We have found that tazobactam is the best among these inhibitors against CTX-M-15. The inhibition characteristic of tazobactam is defined by its very low IC50 value (6 nM), high affinity (Ki=0.017 μM) and better acylation efficiency (k+2/K9=0.44 μM-1s-1). It forms an acyl-enzyme covalent complex, which is quite stable (k+3=0.0057 s-1). Since increasing resistance has been reported against conventional β -lactam antibiotic-inhibitor combinations, we aspire to design a non-β-lactam core containing β-lactamase inhibitor. For this, we screened ZINC database and performed molecular docking to identify a potential non-β-lactam based inhibitor (ZINC03787097). The MICs of cephalosporin antibiotics in combination with this inhibitor gave promising results. Steady-state kinetics and molecular docking studies showed that ZINC03787097 is a reversible inhibitor which binds non-covalently to the active site of the enzyme through hydrogen bonds and hydrophobic interactions. Though, it?s IC50 (180 nM) is much higher than tazobactam, it has good affinity for CTX-M-15 (Ki=0.388 μM). This study concludes that ZINC03787097 compound can be used as seed molecule to design more efficient non-b-lactam containing β -lactamase inhibitor that could evade pre-existing bacterial resistance mechanisms.